Lisata Therapeutics announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to certepetide for the treatment of cholangiocarcinoma. Lisata is currently evaluating certepetide in its BOLSTER trial, a Phase 2a double-blind, placebo-controlled, multi-center, randomized study in the U.S. for the treatment of first- and second-line cholangiocarcinoma.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LSTA:
- Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
- Lisata Therapeutics Announces Q2 2024 Financial Results
- Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- LSTA Earnings this Week: How Will it Perform?
- Lisata Therapeutics treatment of cholangiocarcinoma granted FDA orphan status